Preparation, Optimization and In vitro Evaluation of Doxorubicin‐loaded into Hyaluronic Acid Coated Niosomes Against Breast Cancer

• Published in: Chemistry & biodiversity 2024-02, Vol.21 (2), p.e202301470-n/a
• Main Authors: Faddah, Haya, Nsairat, Hamdi, Shalan, Naeem M., El‐Tanani, Mohamed, Alqudah, Dana A., Alshaer, Walhan
• Format: Article
• Language: English
• Subjects: Breast cancer; Breast Neoplasms - drug therapy; Cell viability; Cytotoxicity; Doxorubicin; Doxorubicin - pharmacology; Electrostatic properties; Entrapment; Female; Freeze drying; Humans; Hyaluronic Acid; Ionic surface active agents; Liposomes; Liquid chromatography; MCF-7 Cells; Niosomes; Self-assembly; Solid tumors; Surfactants; Targeting delivery; Thin films
• ISSN: 1612-1872; 1612-1880
• DOI: 10.1002/cbdv.202301470

Doxorubicin (DOX) is widely used against solid tumors. Niosomes are self‐assembled nanocarriers of non‐ionic surfactants. DOX loaded into cationic niosomes (DOX−Nio) was prepared via thin film hydration method. DOX−Nio was then decorated with a hyaluronic acid (DOX−HA−Nio) via electrostatic interaction. DOX−Nio and DOX−HA−Nio displayed a particle size of 120.0±1.02 and 182.9±2.3 nm, and charge of + 35.5±0.15 and −15.6±0.25 mV, respectively, with PDI < 0.3. DOX−HA−Nio showed a good stability regarding size and charge over 4 weeks at 4 °C and maintain their integrity after lyophilization. HPLC results showed a 94.1±4.2 % encapsulation efficiency of DOX with good entrapment and slow, prolonged DOX release even after 48 hrs. Cell viability assay showed an IC50 of 14.26 nM for the DOX−HA−Nio against MCF‐7 cell line with micromolar IC50 results against CD‐44 negative cell lines (NIH/3T3). DOX−HA−Nio was proven to be an effective, targeted nanocarrier for DOX against MCF‐7 cell line.